Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: Implications for clinical practice and open issues

C. Gridelli, F. De Marinis, M. Di Maio, D. Cortinovis, F. Cappuzzo, T. Mok
  • Lung Cancer, April 2011, Elsevier
  • DOI: 10.1016/j.lungcan.2010.12.009

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

The following have contributed to this page: Dr Federico Cappuzzo